Antheia, a Menlo Park, CA-based pharmaceutical ingredient manufacturer, raised $17M in funding.
The funding included a non-dilutive two-year project agreement up to $11M through the BioMaP Consortium and additional investment from In-Q-Tel, Inc. (IQT), Echo Investment Capital (Echo), and several existing investors, including Viking Global Investors.
The company intends to use the funds for the production of critical pharmaceutical ingredients to the U.S. and accelerating its commercialization strategy.
Led by CEO Christina Smolke, Antheia is a pharmaceutical ingredient producer. Using its novel whole-cell engineering approach, the company’s biomanufacturing platform enables the reconstruction of biosynthetic pathways of complexity in yeast cells and the scaling of fermentation processes to commercial levels. This approach enables on-demand, agile, and resilient biomanufacturing of critical pharmaceutical ingredients, replacing legacy approaches that cannot support the needs of modern healthcare.
FinSMEs
21/07/2024